The effect of alpha-1 antitrypsin (AAT) augmentation therapy on the liver phenotype in individuals with homozygous Pi*Z AAT mutation (genotype Pi*ZZ)

The effect of alpha-1 antitrypsin (AAT) augmentation therapy on the liver phenotype in individuals with homozygous PiZ AAT mutation (genotype PiZZ)

M. Fromme (Aachen, Germany), K. Hamesch (Aachen, Germany), C. Schneider (Aachen, Germany), M. Mandorfer (Vienna, Austria), K. Holtz-Thorhauge (Odense, Denmark), V. Pereira (Funchal, Portugal), M. Pons (Barcelona, Spain), M. Reichert (Homburg, Germany), S. Amzou (Aachen, Germany), R. Bals (Homburg, Germany), R. Koczulla (Marburg, Germany), M. Miravitlles (Barcelona, Spain), S. Janciauskiene (Hannover, Germany), J. Genesca (Barcelona, Spain), F. Benini (Brescia, Italy), J. Chorostowska-Wynimko (Warsaw, Poland), W. Griffiths (Cambridge, United Kingdom), E. Aigner (Salzburg, Austria), A. Teumer (Greifswald, Germany), M. Trauner (Vienna, Austria), A. Krag (Odense, Denmark), C. Trautwein (Aachen, Germany), P. Strnad (Aachen, Germany)

Source: International Congress 2022 – Alpha-1 antitrypsin deficiency and chronic airway obstructive diseases

Session: Alpha-1 antitrypsin deficiency and chronic airway obstructive diseases
Session type: Thematic Poster
Number: 2430

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Fromme (Aachen, Germany), K. Hamesch (Aachen, Germany), C. Schneider (Aachen, Germany), M. Mandorfer (Vienna, Austria), K. Holtz-Thorhauge (Odense, Denmark), V. Pereira (Funchal, Portugal), M. Pons (Barcelona, Spain), M. Reichert (Homburg, Germany), S. Amzou (Aachen, Germany), R. Bals (Homburg, Germany), R. Koczulla (Marburg, Germany), M. Miravitlles (Barcelona, Spain), S. Janciauskiene (Hannover, Germany), J. Genesca (Barcelona, Spain), F. Benini (Brescia, Italy), J. Chorostowska-Wynimko (Warsaw, Poland), W. Griffiths (Cambridge, United Kingdom), E. Aigner (Salzburg, Austria), A. Teumer (Greifswald, Germany), M. Trauner (Vienna, Austria), A. Krag (Odense, Denmark), C. Trautwein (Aachen, Germany), P. Strnad (Aachen, Germany). The effect of alpha-1 antitrypsin (AAT) augmentation therapy on the liver phenotype in individuals with homozygous Pi*Z AAT mutation (genotype Pi*ZZ). 2430

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.